Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8324737 | 0.91 | ALDH1A1 (0.31) | MEN1ALDH1A1ALOX12APOBEC3AKMT2A | |
| SCHEMBL8324513 | 0.87 | — | — | |
| SCHEMBL8323491 | 0.86 | CCKBR (0.33) | MEN1ALDH1A1ALOX12APOBEC3AKMT2A | |
| SCHEMBL8324387 | 0.82 | HDAC3 (0.35) | MEN1ALDH1A1ALOX12APOBEC3AKMT2A | |
| SCHEMBL8325063 | 0.82 | HRH4 (0.38) | HRH4HRH3 | |
| SCHEMBL8322942 | 0.76 | HSP90AA1 (0.36) | KMT2A | |
| SCHEMBL8324137 | 0.75 | PRCP (0.33) | HRH4HRH3 | |
| SCHEMBL8323902 | 0.74 | GRIN2B (0.40) | MEN1KMT2A | |
| SCHEMBL8321485 | 0.74 | HRH4 (0.31) | HRH4HRH3 | |
| SCHEMBL8321181 | 0.74 | RPS6KB1 (0.32) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |